- PAVmed Provides Business Update and First Quarter 2024 Financial Results
- Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
- Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
- Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
- PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
- PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
- Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
More ▼
Key statistics
As of last trade, PAVmed Inc (PAVM:NAQ) traded at 1.79, 11.88% above the 52 week low of 1.60 set on Feb 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.81 |
---|---|
High | 1.82 |
Low | 1.78 |
Bid | 1.78 |
Offer | 1.80 |
Previous close | 1.80 |
Average volume | 68.79k |
---|---|
Shares outstanding | 9.43m |
Free float | 8.84m |
P/E (TTM) | -- |
Market cap | 16.98m USD |
EPS (TTM) | -9.08 USD |
Data delayed at least 15 minutes, as of May 23 2024 16:29 BST.
More ▼